US6136348A - Compound and method for degrading amino acids - Google Patents
Compound and method for degrading amino acids Download PDFInfo
- Publication number
- US6136348A US6136348A US09/205,997 US20599798A US6136348A US 6136348 A US6136348 A US 6136348A US 20599798 A US20599798 A US 20599798A US 6136348 A US6136348 A US 6136348A
- Authority
- US
- United States
- Prior art keywords
- chlorine dioxide
- amino acids
- microorganisms
- concentration
- applying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims description 31
- 230000000593 degrading effect Effects 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 title description 10
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 325
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 163
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 120
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 13
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 229940024606 amino acid Drugs 0.000 claims description 130
- 235000001014 amino acid Nutrition 0.000 claims description 130
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 15
- 229930182817 methionine Natural products 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 235000004279 alanine Nutrition 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 9
- 235000008729 phenylalanine Nutrition 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000004400 serine Nutrition 0.000 claims description 7
- 230000014616 translation Effects 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 235000008521 threonine Nutrition 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000014304 histidine Nutrition 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 235000014705 isoleucine Nutrition 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 235000005772 leucine Nutrition 0.000 claims description 5
- 235000018977 lysine Nutrition 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 235000014393 valine Nutrition 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000009697 arginine Nutrition 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- -1 argenine Chemical compound 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 8
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 239000002674 ointment Substances 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 49
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 35
- 235000019345 sodium thiosulphate Nutrition 0.000 description 35
- 239000001974 tryptic soy broth Substances 0.000 description 35
- 108010050327 trypticase-soy broth Proteins 0.000 description 35
- 239000004133 Sodium thiosulphate Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 241000194019 Streptococcus mutans Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 229930195712 glutamate Natural products 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 244000309466 calf Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 108090000340 Transaminases Proteins 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- XUPLQGYCPSEKNQ-UHFFFAOYSA-H hexasodium dioxido-oxo-sulfanylidene-lambda6-sulfane Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S XUPLQGYCPSEKNQ-UHFFFAOYSA-H 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 150000008575 L-amino acids Chemical class 0.000 description 5
- 235000010419 agar Nutrition 0.000 description 5
- 229940009098 aspartate Drugs 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 229940051866 mouthwash Drugs 0.000 description 5
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 231100000699 Bacterial toxin Toxicity 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 239000000688 bacterial toxin Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000001967 plate count agar Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108091006149 Electron carriers Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000004716 alpha keto acids Chemical class 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- OMJVPFLTCMALSV-UHFFFAOYSA-N 2-(3,5-diethoxy-4-methylsulfanylphenyl)ethanamine Chemical compound CCOC1=CC(CCN)=CC(OCC)=C1SC OMJVPFLTCMALSV-UHFFFAOYSA-N 0.000 description 1
- BTJFGKUKBHSKHI-UHFFFAOYSA-N 2-(3-ethoxy-5-ethylsulfanyl-4-methoxyphenyl)ethanamine Chemical compound CCOC1=CC(CCN)=CC(SCC)=C1OC BTJFGKUKBHSKHI-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- FEMXZDUTFRTWPE-DZSWIPIPSA-N L-erythro-7,8-dihydrobiopterin Chemical group N1C(N)=NC(=O)C2=C1NCC([C@@H](O)[C@@H](O)C)=N2 FEMXZDUTFRTWPE-DZSWIPIPSA-N 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 241000142815 Silene nutans Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical group N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
Definitions
- the present invention relates to degradation of amino acids and, more particularly, to a chlorine dioxide compound for degrading amino acids.
- Organisms as different as the bacterium escherichia coli and humans have many common features at the molecular level. They use the same building blocks to construct macromolecules.
- the flow of genetic information from deoxyribonucleic acid (DNA) to ribonucleic acid (RNA) to protein is essentially the same in both species. Both use adenosine triphosphate (ATP) as a currency of energy.
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- ATP adenosine triphosphate
- a molecule is defined as a combination of two or more atoms. These may be similar atoms such as the combination of two oxygen atoms to make molecular oxygen, O 2 . Most molecules consist of two different elements and structural relationships. All atoms carry electrical charges; some are positive and some are negative. The attraction between the positive and the negative electrical forces binds these into stable molecules which make life possible.
- Molecules described in a textbook are shown as two-dimensional structural formulae. Actually, these are three-dimensional structures with many convolutions, wherein different portions of these molecules and their electrical charges or valence bonds are exposed to other molecular or atomic forces. The strength of these electrical forces, or valence bonds, are the basis for degrees of stability of all living structures.
- the complex molecules of amino acids are structures made up of varying atomic elements, primarily carbon, hydrogen, nitrogen, sulfur and oxygen.
- the essential amino acids in humans are those that must be obtained from food whereas the balance can be endogenously created.
- the strength of the electromotive forces of shared valence bonds is directly related to the stability of a given compound. Molecular oxygen will easily break the valence bonds around sulfur atoms or double bonds between other atoms.
- a chemical compound such as L. cysteine which contains sulfur has a valence bond on a terminal arm with one valence bond to a terminal carbon and another valence bond to a terminal hydrogen. It also has a double bond between a terminal carbon and a molecule of oxygen. These are the weak points of cysteine, making it more easily destroyed by oxidative consumption than some of the other amino acids. The high electromotive forces of oxygen can attack these weaker valence areas, breaking up the arms and oxidatively consuming the molecule. Lynch, using 0.1% chlorine dioxide, has documented the oxidative consumption of cysteine and methionine into pyruvate. (Lynch et al., infra)
- Infections are caused by bacteria, fungi and virus forms and an accepted treatment of infections embraces the reduction of these microorganisms.
- Microorganisms require the presence of amino acids and glycoproteins as building blocks to produce daughter cells. By treating a location of an infection with an aqueous solution of chlorine dioxide, the amino acids and the glycoproteins present will be degraded. Without amino acids or with a reduced presence of amino acids, the growth of microorganism daughter cells will be reduced or curtailed and the infection will be successfully treated.
- Another object of the present invention is to provide chlorine dioxide in an aqueous solution or other vehicle to deprive microorganisms of proteins as building blocks for producing daughter cells.
- Still another object of the present invention is to treat an infection site with an aqueous solution of chlorine dioxide or chlorine dioxide in another vehicle such as a gel to degrade amino acids and glycoproteins and prevent microorganisms from making new proteins.
- Yet another object of the present invention is to alter the amino acid milieux of the oral, vaginal and other body cavities.
- a further object of the present invention is to remove cellular debris from internal and external tissue surfaces of animals and man.
- a still further object of the present invention is to reduce microbial growth upon dental prosthetics and other appliances.
- a yet further object of the present invention is to provide an aqueous solution of chlorine dioxide to reduce the growth of microorganisms by degrading amino acids present.
- FIG. 1 is a bar chart illustrating the destruction of S. mutans in the presence of chlorine dioxide.
- Transaminases catalyze the transfer of the alpha amino group of many alpha amino acids to alpha ketoglutarate to form glutamate, which is then oxidatively deaminated to yield ammonia.
- Glutamate transaminase the most important of these enzymes, catalyzes the transfer of an amino group to alpha ketoglutarate.
- alpha amino acid plus alpha ketoglutarate can produce or reduce from alpha keto acid plus glutamate.
- Alanine transaminase which is ubiquitous in mammalian tissue, catalyzes the transfer of an amino group to pyruvate.
- alpha amino acid from pyruvate will form or reduce from alpha keto acid and alanine.
- the alanine group in this step can transfer its amino group to alpha keto glutarate to form glutamate.
- These two transaminases funnel alpha amino groups from a variety of amino acids into glutamate for conversion into ammonia.
- Ammonium ion is formed from glutamate by oxidative deamination, catalyzed by glutamate dehydrogenase, which is unusual in being able to utilize either NAD or NADP. This is another step in the use of oxygen in the deamination process.
- amino acids shows the amount of double bonds plus the presence of sulfur atoms in the formation of some amino acids. These can be used to become building blocks to form protein. However, when in excess and in the presence of oxygen, they can be converted into compounds such as pyruvate or glutamate to enter the citric acid cycle and produce energy.
- the three-carbon family amino acids, alanine, cerine, cysteine and threonine, are converted to pyruvate by the presence or addition of oxygen.
- Pyruvate is the entry point for the three-carbon amino acids: alanine, serine and cysteine. The transamination of alanine directly yields pyruvate:
- Aspartate a four-carbon amino acid, is directly transaminated to oxaloacetate, a citric acid cycle intermediate:
- Asparagine is hydrolyzed by asparaginase to NH 4 + and aspartate, which is then transaminated. Aspartate can also be converted into fumarate by the urea cycle. Fumarate is also a point of entry for half of the carbon atoms of tyrosine and phenylalanine.
- the pathway for the degradation of phenylalanine and tyrosine shows how molecular oxygen is used to break an aromatic ring.
- the first step is the hydroxylation phenylalanine to tyrosine, a reaction catalyzed by the mono-oxygenase enzyme phenylalanine hydroxylase. ##STR4##
- the reductant here is tetrahydrobiopterin, an electron carrier.
- the oxidized form of this electron carrier is dihydrobiopterin.
- polypeptide chain In the development of protein, many amino acids are joined by peptide bonds to form a polypeptide chain, which is an unbranched structure.
- a polypeptide chain has direction because its building blocks have different ends, namely the alpha-amino and the alpha carboxyl groups. By convention, the amino end is taken to be the beginning of a polypeptide chain. The sequence of amino acids in a polypeptide chain is written starting with the amino terminal residue.
- a polypeptide chain consists of a regularly repeating part called the main chain and a variable part, comprising a distinctive side chain.
- a few side chains are cross-linked by disulfide bonds. These crosslinks are formed by the oxidation of cysteine residues. Resulting disulfide is called cysteine. No other co-valent crosslinks are generally found in proteins.
- Polypeptide chains are the basis of the cell walls of all cells of all living organisms.
- the polypeptide chain is made up of molecules containing many double bonds and many sulfur bonds, the chain may be broken by a compound of high redox capacity.
- Chlorine dioxide is known as having one of the highest redox capacities of any of the compounds known to man.
- exposing individual amino acids or exposing the polypeptide chain of a dead cell to chlorine dioxide makes it an easy target for its disintegration.
- the body fluids such as saliva or vaginal fluid of animals, including humans, contain many organic compounds. Some of these are glycoproteins which contain atoms associated with double bonds and, like amino acids, are susceptible to degradation by chlorine dioxide. The degradation by-products from dead epithelial cells, dead bacteria and food debris residues form a pool of amino acids which are used for the nutrition of microbial populations.
- the novelty of this invention is to reduce the availability of amino acids and/or glycoproteins in a given environment. It is not to create a toxicity in either the bacteria or host but rather a change in a local environment wherein bacteria are deprived of the amino acid building blocks for protein formation necessary for microorganisms to produce daughter cells.
- Chlorine dioxide is capable of degrading amino acids.
- the work of Lynch and coworkers showed that cysteine and methionine are degraded into pyruvate in the presence of chlorine dioxide.
- the chemical change was documented using nuclear magnetic spin resonance. Grootveld et al studied microbial population in dental students which showed when they used chlorine dioxide in an oral rinse, the microbial counts were reduced.
- Amino acids are the essential building blocks for protein formation for cell walls. Protein is a requirement for all living creatures. Without the building blocks of amino acids, there is no protein and no life. Chlorine dioxide oxidatively consumes amino acids thus altering them into other compounds, primarily pyruvate or glutamate. Thus, the absence of amino acids as building blocks for life creates an environment which prevents the growth of microorganisms.
- Study 1 shows degradation of all the amino acids at their natural pH (as evaluated by liquid chromatography).
- the most important amino acids are cysteine and methionine in oral malodor and regarding DNA synthesis in production of new daughter cells.
- Methionine is the lead couplet on transfer ribonucleic acid (tRNA). Destruction of methionine in tRNA prevents the synthesis of protein.
- Oral maloder is the first step in the etiology of gingivitis and periodontitis. Inflammation of oral and other mucous membranes is caused by the penetration of bacterial toxins through surface epithelium into subepithelial connective tissue.
- the malodor compounds hydrogen sulfide (H 2 S) derived from cysteine and methylmercaptam (CH 3 SH) derived from methionine are well documented to be facilitating permeation agents allowing bacterial toxins through the intact healthy protective epithelium. Ratcliff, Perry A. and Johnson, Paul/Sequence of Events in the Pathogenesis of Gingivitis and Periodontitis (Accepted for publication by Journal of Periodontology).
- Methionine which had a control baseline of 306 ppm which went to 89 ppm.
- Formylmethionine is the lead couplet of all bacterial tRNA, and its removal intercepts bacterial mitosis. It prevents bacterial secretion of peptides and enzymes. Cysteine went from 124 ppm to 1 ppm in five minutes. Phenylalanine went from 333 to 220 ppm in five minutes.
- the ClO 2 is added to the amino acid in its natural pH milieu, the amino acid undergoes degradation. This denies 1) cell multiplication by deprivation of building blocks to produce and transfer new DNA for cell replication and 2) cell wall polypeptides.
- ClO 2 can degrade amino acid building blocks for DNA synthesis and cell wall polypeptide chains.
- the minimum amount of concentrated sodium thiosulphate needed to completely neutralize the chlorine dioxide was determined to be 1.0 ml of 10% concentrate.
- the chlorine dioxide was neutralized at 1 minute for the first vial, 3 minutes for the second vial, and 5 minutes for the third vial.
- the concentration of amino acids were significantly lower in the control (0 min) sample than the expected values. This may be due to negative interferences(s) caused by the presence of a neutralized oxidant in the matrix. The exact nature of the interference(s) could not accurately be determined, and therefore could not be controlled.
- the amino acid concentrations may also have been subject to positive matrix interference(s) as some exhibited an increase over time.
- Study 2 is a repeat of Study 1 wherein the pH was adjusted to 6.5, which is the pH of RetarDex a trademark of Rowpar Pharmaceuticals, Inc., oral rinse and the pH of a healthy mouth. There are differences in reactivity of cysteine and methionine in a healthy oral environment vs. a more acid environment. Also, there was no change in tryptophan.
- a stock amino acid solution was prepared in de-ionized water to contain 0.1% of each amino acid and the pH adjusted to 6.5 with IN hydrochloric acid or 1N sodium hydroxide.
- the chlorine dioxide was neutralized at 1 minute for the first vial, 3 minutes for the second vial, and 5 minutes for the third vial.
- the chlorine dioxide concentration of the concentrated stock was 5.11%.
- the 0 minute control was 0.0998% chlorine dioxide.
- the chlorine dioxide concentrations and percent decrease at 1, 3 and 5 minutes are shown on page 27.
- Studies 1-3 When compared to baseline, select amino acids were degraded after 5 minutes or less when treated with an 0.1% chlorine dioxide solution. The greatest reduction was with cysteine and methionine. Since these two amino acids are major molecules in riboneucleic acid and in deoxyribonecleic acid and are part of the polypeptide chain which forms the cell wall of microorganisms, the potential availability of these building blocks should reduce the potential mitotic capacity of bacteria. Study #3 evaluated the quantity of loss of ClO 2 when mixed with each amino acid. This provided further proof of interaction between ClO 2 and this family of compounds.
- the chlorine dioxide concentration of the concentrated stock was 5.11%.
- the 0 minute control was 0.0998% chlorine dioxide.
- the chlorine dioxide concentrations and percent decrease at 1, 3 and 5 minutes are as follows:
- Study 4 is to evaluate tryptophan which is an important amino acid in the formation of protein from amino acids. Tryptophan was exposed to ClO 2 for determination of the changes that might take place. Tryptophan untreated was the control
- the minimum amount of concentrated sodium thiosulphate needed to completely neutralize the chlorine dioxide was determined to be 1.0 ml of 10% concentrate.
- the chlorine dioxide was neutralized at 1 minute for the first vial, 3 minutes for the second vial, and 5 minutes for the third vial.
- TSB tryptic soy broth
- TSB is a culture medium for gram positive bacteria. This study was to determine if the change that occurred was a result of the exposure of bacteria to TSB plus the 0.1% ClO 2 versus TSB without the 0.1 ClO 2 formulation. Any there be a change in the growth medium rather than a change on the bacteria? Consequently, prior to inoculation with the test bacteria, the growth medium was treated with ClO 2 and then the ClO 2 removed from the medium by the thiosulfate procedure as used in the earlier experiments.
- ClO 2 degrades amino acids in the growth medium, denying building blocks to produce bacterial daughter cells.
- TSB was seeded with 0.1% and incubated for 24 hours at 35° C. Subsequent to incubation the residual chlorine dioxide was determined iodometrically.
- TSB Three ten-milliliter aliquots of TSB were spiked with 0.011% chlorine dioxide, the amount consumed in 24 hours, incubated for 24 hours at 35° C. and inoculated with 3,600 colony forming units of S. mutans. Three 10-milliliter aliquots of non-chlorine dioxide treated TSB were inoculated as a control.
- Study 6 verifies the same observations as in Study #5 using tryptic soy agar and Streptococcus mutans as a marker. This demonstrates that you can obliterate the growth of S. mutans with
- a suspension of S. nutans was prepared in Butterfield's buffer and the concentration of viable bacteria determined utilizing the standard plate count method.
- Solidified plates from each aliquot were inoculated with S. mutans stock to yield ⁇ 60 CFU/plate.
- the plates were incubated at 35° C. for 72 hours. At 24 hour intervals, the colonies were enumerated and described by colony presentation.
- the chlorine dioxide and sodium thiosulphate treated blood agar plates did not support the growth of Streptococcus mutans.
- Study 7 The FDA requires the addition of calf serum to TSB when one is attempting to simulate the oral environment. This is because TSB does not have the full amino acid content of human saliva which largely exists in calf serum. Accordingly, Study 6 repeats Study 5 with the substitution of calf serum instead of TSB as a growth medium. It showed that with a common time exposure, untreated TSB had 910,000 colony forming units (CFU) of the test organisms, S. mutans, whereas the TSB treated with ClO 2 had an average of 860 CFU. This suggests that the use of ClO 2 results in a reduction of amino acid nutrients for the formation of bacterial daughter cells.
- CFU colony forming units
- TSB 5 ml
- TSB was seeded with 0.1% chlorine dioxide, incubated for 24 hours at 35° C. and any residual chlorine dioxide neutralized with 1 ml 10% sodium thiosulphate. Portions of each test solutions were aliquoted into each of three sterile 16 ⁇ 125-mm test tubes. As a control, a portion of TSB was also treated with neutralized sodium thiosulphate as above.
- Study 8 was a control where the amino acids had received sodium thiosulfate only, with no addition of ClO 2 . Inasmuch as the thiosulfate was used to neutralize the ClO 2 in previous studies, there was a need to document that the amino acids were not affected by the thiosulfate, only by the ClO 2 .
- a solution of the three amino acids was prepared in deionized water at a concentration of 2,750 ppm and adjusted to pH 6.5. The solution was aliquoted into two test tubes. One milliliter of deionized water was added to the first tube and 1 milliliter of 10% sodium thiosulphate added to the second. The samples were analyzed for amino acid content by Woodson-Tenent Laboratories in Des Moines, Iowa.
- LAL Limulus Amebocyte Lysate test kit, manufactured by Charles River Endosafe, Lot No. L1042L, Exp 10/2000, 0.25 EU/ml.
- the purified LPS was reconstituted with 10 ml endotoxin free water to yield a concentration of 100,000 EU per milliliter.
- the endotoxin suspension was aliquoted into ten depyrogenated test tubes (13 ⁇ 100 mm), 1 ml per tube and the temperature equilibrated to 37° C. Each of the ten aliquots were treated with 19 ul of 5.3% chlorine dioxide to yield a final concentration of 0.1% chlorine dioxide.
- Each of the solutions was allowed to react as shown in Table 9A below. After the reaction time, 100 ul of 20% sodium thiosulphate was added to the solution to neutralize any unreacted chlorine dioxide. For the zero time point, the chlorine dioxide was neutralized with sodium thiosulphate prior to addition to the endotoxin stock solution. After the reaction period, each tube was quantified for endotoxins employed the LAL test kit.
- LAL Limulus Amebocyte Lysate test kit, manufactured by Charles River Endosafe, Lot No. L, 042L, Exp 10/2000, 0.25 EU/ml.
- the purified LPS was reconstituted with 100 ml endotoxin free water to yield a concentration of 10,000 EU per milliliter.
- the endotoxin suspension was aliquoted into ten depyrogenated test tubes (13 ⁇ 100 mm), 1 ml per tube and the temperature equilibrated to 37° C., Each of the ten aliquots were treated with 19 ul of 5.3% chlorine dioxide to yield a final concentration of 0.1% chlorine dioxide.
- Each of the solutions was allowed to react as shown in Table 9B below. After the reaction time, 100 ul of 20% sodium thiosulphate was added to the solution to neutralize any unreacted chlorine dioxide. For the zero time point, the chlorine dioxide was neutralized with sodium thiosulfate prior to addition to the endotoxin stock solution. After the reaction period, each tube was quantified for endotoxins employed the LAL test kit.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Alanine+alpha-ketoglutarate⃡pyruvate+glutamate ##STR1## The C.sub.4 Family: Aspartate and Asparagine Are Converted Into Oxaloacetate
Aspartate+alpha-ketoglutarate⃡oxaloacetate+glutamate
TABLE 1 ______________________________________ AMINO ACID CONCENTRATION AFTER SPECIFIED TREATMENT Amino Acid Baseline 1 ml ______________________________________ Essential Arginine 357 340 310 230 35.574% Histidine 318 260 250 160 49.686 Isoleucine 269 200 210 170 36.803 Leucine 269 210 210 210 21.933 Lysine 300 230 240 200 33.333 Methionine 306 130 110 89 70.915 Phenylalanine 339 280 270 220 35.103 Threonine 244 190 190 180 26.230 Tryptophan Valine 240 180 190 150 37.500 Nonessential Alanine 183 150 150 140 23.497% Aspartic acid 273 240 230 240 12.088 Cysteine 124 3 2 1 99.194 Glutamic 302 260 260 270 10.695 acid Glycine 287 130 120 92 67.944 Proline 236 210 200 220 6.780 Serine 215 160 160 120 44.186 Tyrosine 316 310 290 230 26.445 ______________________________________
TABLE 2 ______________________________________ Amino Acid Concentrations When Treated with 0.1% Chlorine Dioxide Amino Acid Concentrations (%) After Specified Treatment TimesAmino Acid Control 0 min. 1 min. 3 min. 5 min. ______________________________________ Alanine 0.45 0.46 0.43 0.43 0.44 Arginine 0.36 0.37 0.41 0.43 0.44 Aspartic Acid 0.51 0.55 0.46 0.46 0.48 Cysteine 0.22 0.07 0.01 0.01 0.01 Glutamic Acid 0.51 0.54 0.51 0.52 0.54 Glycine 0.66 0.65 0.61 0.61 0.64 Histidine 0.34 0.35 0.30 0.28 0.30 Hydroxyproline 0.47 0.84 0.71 0.71 0.72 Isoleucine 0.44 0.44 0.41 0.42 0.43 Leucine 0.45 0.45 0.42 0.43 0.44 Lysine 0.38 0.39 0.35 0.35 0.36 Methionine 0.47 0.49 0.30 0.29 0.29 Phenylalanine 0.46 0.47 0.43 0.44 0.45 Proline 0.32 0.33 0.33 0.32 0.35 Serine 0.53 0.52 0.51 0.51 0.52 Tryptophan 0.06 0.06 0.06 0.06 0.06 Threonine 0.45 0.45 0.43 0.43 0.45 Tyrosine 0.46 0.46 0.43 0.43 0.43 Valine 0.46 0.46 0.43 0.42 0.43 ______________________________________
TABLE 3 ______________________________________ Chlorine Dioxide Concentrations and Percent Decrease L-Amino % De- % De- % De- Acids pH 1 min crease 3 min crease 5 min crease ______________________________________ Alanine 5.3 0.0962 3.6 0.0962 3.6 0.0962 3.6 Arginine 5.3 0.0932 6.6 0.0932 6.6 0.0928 7.0 Aspara- 3.7 0.0972 2.6 0.0962 3.6 0.0972 2.6 gine Aspartic 2.8 0.0975 2.3 0.962 3.6 0.0958 4.0 Acid Cysteine 3.7 0.0912 8.6 0.0925 7.3 0.0925 7.3 Glutamic 2.9 0.0978 2.0 0.0958 4.0 0.0958 4.0 Acid Glutamine 3.8 0.0982 1.6 0.0952 4.6 0.0958 4.0 Glycine 5.1 0.0968 3.0 0.0965 3.3 0.0958 4.0 Histidine 3.5 0.0978 2.0 0.0972 2.6 0.0975 2.3 Hydroxy- 4.7 0.0975 2.3 0.0975 2.3 0.0978 2.0 proline Isoleucine 5.0 0.0978 2.0 0.0975 2.3 0.0972 2.6 Leucine 5.0 0.0952 4.6 0.0958 4.00 0.0958 4.0 Lysine 5.2 0.0985 1.3 0.0978 2.0 0.972 2.6 Methio- 4.9 0.0787 21.1 0.0793 20.5 0.0793 20.5 nine Phenylala- 5.0 0.0985 1.3 0.0978 2.0 0.0978 2.0 nine Proline 5.5 0.0968 3.0 0.0975 2.3 0.0982 1.6 Serine 5.1 0.0982 1.6 0.0982 1.6 0.0975 2.3 Threonine 5.0 0.0975 2.3 0.0975 2.3 0.0978 2.0 Trypto- 4.9 0.0516 48.3 0.0529 47.0 0.0522 47.7 phan Tyrosine 5.5 0.0995 0.3 0.0992 0.6 0.0992 0.6 Valine 5.8 0.0998 0 0.0988 0 0.0992 0.6 ______________________________________
TABLE 4 ______________________________________ Results Showing the Effect of Chlorine Dioxide on Acidified Tryptophan Tryptophan (PPM)Amino Acid Control 0 min. 1 min. 3 min. 5 min. ______________________________________ Tryptophan 1,600 1,100 900 600 400 ______________________________________
______________________________________ 1. Tryptic Soy Broth (TSB), formula per liter: a. Pancreatic digest of casein 17.0 g b. Sodium chloride 5.0 g c. Papaic digest of soybean meal 3.0 g d. K.sub.2 HPO.sub.4 2.5 g e. Glucose 2.5g 2. Streptococcus mutans, ATCC#25175 3. Plate Count Agar 4. Chlorine dioxide ______________________________________
TABLE 5 ______________________________________ Solution Culture Media S. mutans (CFU per milliliter) ______________________________________ 1 TSB 360,000,000 2 TSB 400,000,000 3 TSB 510,000,000 Average TSB 420,000,000 4 TSB + 0.011% ClO2 65,000,000 5 TSB + 0.011% ClO2 9,000,000 6 TSB + 0.011% ClO2 46,000,000 Average TSB + 0.011% ClO2 40,000,000 ______________________________________
TABLE 6 ______________________________________ Colony No. of Colony No. of Colony No. of size colonies size (48 colonies size (72 colonies Agar tested (24 hr.) (24 hr.) hr.) (48 hr.) hr.) (72 hr.) ______________________________________ Control (No 1 mm 12 1 mm 145 1 mm 145 treatment) ClO.sub.2 treated N/A 0 N/A 0 N/A 0 agar Na.sub.2 S.sub.2 O.sub.3 N/A 0 N/A 0 N/A 0 treated agar ______________________________________
______________________________________ 1. Tryptic Soy Broth (TSB), formula per liter: a. Pancreatic digest of casein 17.0 g b. Sodium chloride 5.0 g c. Papaic digest of soybean meal 3.0 g d. K.sub.2 HPO.sub.4 2.5 g e. Glucose 2.5g 2. Calf serum 3. Streptococcus mutans, ATCC#25175 4. Plate Count Agar 5. Chlorine dioxide ______________________________________
TABLE 7 ______________________________________ S. mutans (CFU per milliliter) Growth No. Matrix ClO.sub.2 1 2 3 Average ______________________________________ 1 Tryptic No 2,300,000 2,000,000 2,100,000 2,100,000Soy Broth 2 Tryptic Yes 760 870 940 860 Soy Broth 3 Calf No 780,00 840,000 1,100,000 910,000 Serum 4 Calf Yes <10 <10 <10 <10 Serum ______________________________________
TABLE 8 ______________________________________ Amino Acids + Sodium Amino Acid Amino Acids + Water thiosulphate ______________________________________ Cystine 3,200 2,700 Methionine 3,000 3,000 Tryptophan 2,500 2,400 ______________________________________
TABLE 9A ______________________________________ Reaction Time Endotoxin No. (Min) 5.3% ClO.sub.2 (ul) 20% Na.sub.2 S.sub.2 O.sub.2 Stock (ml) ______________________________________ 1 0 19 100 1 2 1 19 100 1 3 3 19 100 1 4 5 19 100 1 5 30 19 100 1 6 60 19 100 1 7 120 19 100 1 8 180 19 100 1 9 240 19 100 1 10 300 19 100 1 ______________________________________
TABLE 9AA ______________________________________ Results Showing the Effect of 0.1% Chlorine Dioxide on Lipopolysaccharide of E. coli 055:B5 Reaction Time Chlorine Dioxide Endotoxin No. (Min) (%) (EU/ml) ______________________________________ 1 0 0.1 ≧100,000 2 1 0.1 ≧100,000 3 3 0.1 ≧100,000 4 5 0.1 ≧100,000 5 30 0.1 ≧100,000 6 60 0.1 ≧100,000 7 120 0.1 ≧100,000 8 180 0.1 ≧100,000 9 240 0.1 ≧100,000 10 300 0.1 ≧100,000 Control 1 0 0 <0.25Control 2 0 0 <0.25 Control 3 0 0.1 <0.25 Control 4 0 0.1 <0.025 Control 5 0 0.1 ≧0.25 ______________________________________
TABLE 9B ______________________________________ Reaction Time Endotoxin No. (Hour) 5.3% ClO.sub.2 (ul) 20% Na.sub.2 S.sub.2 O.sub.3 Stock (ml) ______________________________________ 1 0 19 100 1 2 1 19 100 1 3 12 19 100 1 4 24 19 100 1 ______________________________________
TABLE 9BB ______________________________________ Results Showing the Effect of 0.1% Chlorine Dioxide on Lipopolysaccharide of E. coli 055:B5. Reaction Time Chlorine Dioxide Endotoxin No. (Hour) (%) (EU/ml) ______________________________________ 1 0 0.1 ≧10,000 2 1 0.1 ≧10,000 3 12 0.1 ≧10,000 4 24 0.1 ≧10,000 Control 1 0 0 <0.25Control 2 0 0 <0.25 Control 3 0 0.1 <0.25 Control 4 0 0.1 <0.25 Control 5 0 0.1 ≧0.25 ______________________________________
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/205,997 US6136348A (en) | 1997-12-05 | 1998-12-04 | Compound and method for degrading amino acids |
AU21607/00A AU2160700A (en) | 1998-12-04 | 1999-11-30 | Compound and method for degrading amino acids |
PCT/US1999/028320 WO2000033852A1 (en) | 1998-12-04 | 1999-11-30 | Compound and method for degrading amino acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6758597P | 1997-12-05 | 1997-12-05 | |
US09/205,997 US6136348A (en) | 1997-12-05 | 1998-12-04 | Compound and method for degrading amino acids |
Publications (1)
Publication Number | Publication Date |
---|---|
US6136348A true US6136348A (en) | 2000-10-24 |
Family
ID=22764557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/205,997 Expired - Lifetime US6136348A (en) | 1997-12-05 | 1998-12-04 | Compound and method for degrading amino acids |
Country Status (3)
Country | Link |
---|---|
US (1) | US6136348A (en) |
AU (1) | AU2160700A (en) |
WO (1) | WO2000033852A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090017548A1 (en) * | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Method for Determining the Effectiveness of Stabilized Chlorine Dioxide in a Mouth Rinse |
US20100074970A1 (en) * | 2008-08-26 | 2010-03-25 | Micropure, Inc. | Method and composition for preventing and healing osteonecrosis of the jaw |
US8636987B2 (en) | 2008-07-15 | 2014-01-28 | Basf Corporation | Tooth whitening compositions and methods |
US8703106B2 (en) | 2009-02-04 | 2014-04-22 | Basf Corporation | Chlorine dioxide treatment for biological tissue |
US9211240B2 (en) | 2012-02-10 | 2015-12-15 | Periproducts Ltd | Multicomponent oral care composition |
EP3115083A1 (en) | 2010-03-25 | 2017-01-11 | Micropure, INC. | Composition and method for preventing oral disease |
US9937204B2 (en) | 2008-07-10 | 2018-04-10 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
US11000710B2 (en) | 2009-02-13 | 2021-05-11 | Micropure, Inc. | Composition and method for the generation of chlorine dioxide from the oxidative consumption of biomolecules |
US11406577B2 (en) | 2017-09-01 | 2022-08-09 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489435A (en) * | 1993-07-06 | 1996-02-06 | Ratcliff; Perry A. | Composition for treatment of abnormal conditions of the epithelium of bodily orifices |
US5616347A (en) * | 1995-02-14 | 1997-04-01 | Alliger; Howard | Chlorine dioxide skin medicating compositions for preventing irritation |
-
1998
- 1998-12-04 US US09/205,997 patent/US6136348A/en not_active Expired - Lifetime
-
1999
- 1999-11-30 WO PCT/US1999/028320 patent/WO2000033852A1/en active Application Filing
- 1999-11-30 AU AU21607/00A patent/AU2160700A/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
"The Inhibitory Effect of Alcide®, An Antimicrobial Drug, On Protein Synthesis in Escherichia coli", by JoAnn Scatina and Mohamed S. Abdel-Rahman, Journal of Applied Technology, vol. 5, No. 6, 1985, pp. 388-394. |
Article entitled "Protein Synthesis", Chapter 27, Biochemistry, Second Edition, by Lubert Stryer, Stanford University, W.H. Freeman and Company, San Francisco, 6 pages. |
Article entitled Protein Synthesis , Chapter 27, Biochemistry , Second Edition, by Lubert Stryer, Stanford University, W.H. Freeman and Company, San Francisco, 6 pages. * |
The Inhibitory Effect of Alcide , An Antimicrobial Drug, On Protein Synthesis in Escherichia coli , by JoAnn Scatina and Mohamed S. Abdel Rahman, Journal of Applied Technology , vol. 5, No. 6, 1985, pp. 388 394. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090017548A1 (en) * | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Method for Determining the Effectiveness of Stabilized Chlorine Dioxide in a Mouth Rinse |
US7875460B2 (en) | 2007-07-09 | 2011-01-25 | Micropure, Inc. | Method for determining the effectiveness of stabilized chlorine dioxide in a mouth rinse |
US9937204B2 (en) | 2008-07-10 | 2018-04-10 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
US8636987B2 (en) | 2008-07-15 | 2014-01-28 | Basf Corporation | Tooth whitening compositions and methods |
US20100074970A1 (en) * | 2008-08-26 | 2010-03-25 | Micropure, Inc. | Method and composition for preventing and healing osteonecrosis of the jaw |
US8697141B2 (en) | 2008-08-26 | 2014-04-15 | Micropure, Inc. | Method and composition for preventing and healing osteonecrosis of the jaw |
US8703106B2 (en) | 2009-02-04 | 2014-04-22 | Basf Corporation | Chlorine dioxide treatment for biological tissue |
US11000710B2 (en) | 2009-02-13 | 2021-05-11 | Micropure, Inc. | Composition and method for the generation of chlorine dioxide from the oxidative consumption of biomolecules |
EP3115083A1 (en) | 2010-03-25 | 2017-01-11 | Micropure, INC. | Composition and method for preventing oral disease |
US9211240B2 (en) | 2012-02-10 | 2015-12-15 | Periproducts Ltd | Multicomponent oral care composition |
US9408788B2 (en) | 2012-02-10 | 2016-08-09 | Periproducts Ltd | Multicomponent oral care composition |
US11406577B2 (en) | 2017-09-01 | 2022-08-09 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
WO2000033852B1 (en) | 2000-12-14 |
WO2000033852A1 (en) | 2000-06-15 |
AU2160700A (en) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Frenkel et al. | Spontaneous development of L forms of streptococci requiring secretions of other bacteria or sulphydryl compounds for normal growth | |
US5489435A (en) | Composition for treatment of abnormal conditions of the epithelium of bodily orifices | |
Duncan et al. | Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate | |
Frank et al. | On the biosynthesis of pyocyanine | |
US5200171A (en) | Oral health preparation and method | |
US5348734A (en) | Oral health preparation and method | |
US6136348A (en) | Compound and method for degrading amino acids | |
BR9813021A (en) | Process for microbial preparation of amino acids from the aspartate and / or glutamate family and agent used in the process | |
CZ245696A3 (en) | Application form, sterilization preparation, additional feeding stuff and sterilization process | |
ATE305720T1 (en) | BACTERICIDAL DISINFECTANT PERACETIC ACID COMPOSITION | |
EA002686B1 (en) | Substance for producing water suitable for aquatic animals | |
Liu | Factors that influence toxigenicity of Pseudomonas aeruginosa | |
Jacangelo et al. | Oxidation of sulfhydryl groups by monochloramine | |
Gharbia et al. | The influence of peptides on the uptake of amino acids in Fusobacterium; predicted interactions with Porphyromonas gingivalis | |
Yoon et al. | The antimicrobial effect of fluorides (acidulated phosphate, sodium and stannous) on Actinomyces viscosus | |
Kawada et al. | Purification of 6-phosphogluconolactonase from rat liver and yeast; its separation from gluconolactonase | |
Shechter et al. | Influence of protease inhibitors and energy metabolism on intracellular protein breakdown in starving Escherichia coli | |
Warn-Cramer et al. | Markedly different ascorbate dependencies of the sequential alpha-ketoglutarate dioxygenase reactions catalyzed by an essentially homogeneous thymine 7-hydroxylase from Rhodotorula glutinis. | |
Bailey et al. | The reversal of antibiotic action | |
WO2022171153A1 (en) | Disinfectant | |
JPS57115179A (en) | Immobilized enzymatic active substance and its preparation | |
EP0613678A1 (en) | Oral care composition | |
PT81283B (en) | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR DISINFECTION AND STERILIZATION TAMPONATED WITH GLUTARALDEIDO | |
Norrod et al. | Presence of hydrogen peroxide in media used for cultivation of Neisseria gonorrhoeae | |
US4661457A (en) | Method for cultivation of pseudomonas bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: PERRY A. RATCLIFF AND ROBERTA R. RATCLIFF REVOCABL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RATCLIFFE, PERRY A., MR.;REEL/FRAME:021617/0128 Effective date: 20080930 |
|
AS | Assignment |
Owner name: PERRY A. RATCLIFF & ROBERTA R. RATCLIFF REVOCABLE Free format text: CORRECTIVE COVER SHEET DOC ID 500665466 TO CORRECT THE ASSIGNOR NAME REEL/FRAME 021617/0128;ASSIGNOR:RATCLIFF, PERRY A.;REEL/FRAME:021640/0583 Effective date: 20080930 |
|
AS | Assignment |
Owner name: MICROPURE, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERRY A. RATCLIFF & ROBERTA R. RATCLIFF REVOCABLE TRUST;REEL/FRAME:022162/0242 Effective date: 20090124 |
|
FPAY | Fee payment |
Year of fee payment: 12 |